Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Foresee Pharmaceuticals Co., Ltd. (6576.TWO)
Taipei, TPE, TW
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases. Foresee Pharmaceuticals Co., Ltd. was incorporated in 2013 and is based in Taipei, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.63% | -3.75% | +3.25% | -5.24% | +2.58% | -1.36% | +23.83% | -7.16% | -1.11% | +7.77% | -23.93% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+3.0% Q1'26: -27.3% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+27.6% ★ Q1'26: +236.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-220.0% Q1'26: -173.6% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-200.0% Q1'26: -169.4% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%-187.0% Q1'26: -112.2% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+12.8% Q1'26: +1.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-0.27× Q1'26: -0.43× (vs Q1'25)
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
26.00M
est.
|
75.20M
est: 75.00M (+0.3%)
|
230.44M
est: 210.50M (+9.5%)
|
226.03M
est: 227.33M (-0.6%)
|
301.51M
est: 300.00M (+0.5%)
|
195.04M
est: 197.25M (-1.1%)
|
418.69M
est: 425.00M (-1.5%)
|
431.27M
est: 700.00M (-38.4%)
|
540.26M
540.26M – 540.26M
-22.8% YoY
|
676.80M
676.80M – 676.80M
+25.3% YoY
|
| EBITDA |
-26.00M
est.
|
-442.90M
est: -75.00M (-490.5%)
|
-432.33M
est: -210.50M (-105.4%)
|
-475.83M
est: -227.33M (-109.3%)
|
-386.58M
est: -300.00M (-28.9%)
|
-912.16M
est: -197.25M (-362.4%)
|
-945.98M
est: -425.00M (-122.6%)
|
-862.32M
est: -700.00M (-23.2%)
|
-540.26M
-540.26M – -540.26M
+22.8% YoY
|
-676.80M
-676.80M – -676.80M
-25.3% YoY
|
| EBIT |
-26.00M
est.
|
-469.46M
est: -75.00M (-525.9%)
|
-481.82M
est: -210.50M (-128.9%)
|
-527.31M
est: -227.33M (-132.0%)
|
-437.73M
est: -300.00M (-45.9%)
|
-985.79M
est: -197.25M (-399.8%)
|
-1.03B
est: -425.00M (-141.5%)
|
-862.32M
est: -700.00M (-23.2%)
|
-540.26M
-540.26M – -540.26M
+22.8% YoY
|
-676.80M
-676.80M – -676.80M
-25.3% YoY
|
| Net Income |
-727.26M
est.
|
-487.21M
est: -711.26M (+31.5%)
|
-510.71M
est: -390.50M (-30.8%)
|
-569.27M
est: -641.34M (+11.2%)
|
-472.64M
est: -522.07M (+9.5%)
|
-1.04B
est: -948.67M (-9.2%)
|
-1.08B
est: -816.53M (-32.4%)
|
-883.15M
est: -768.50M (-14.9%)
|
1.74B
1.74B – 1.74B
+327.0% YoY
|
1.74B
1.74B – 1.74B
+0.0% YoY
|
| SGA |
13.24M
est.
|
109.32M
est: 38.20M (+186.2%)
|
120.58M
est: 107.21M (+12.5%)
|
99.07M
est: 115.79M (-14.4%)
|
124.23M
est: 152.80M (-18.7%)
|
160.16M
est: 100.46M (+59.4%)
|
147.32M
est: 171.98M (-14.3%)
|
—
est: 283.27M (-100.0%)
|
218.63M
218.63M – 218.63M
-22.8% YoY
|
273.88M
273.88M – 273.88M
+25.3% YoY
|
| EPS |
-5.30
est.
|
-5.08
est: -5.18 (+1.9%)
|
-4.98
est: -2.84 (-75.1%)
|
-4.80
est: -4.67 (-2.8%)
|
-4.00
est: -3.80 (-5.2%)
|
-8.14
est: -6.91 (-17.8%)
|
-7.87
est: -5.27 (-49.3%)
|
-5.70
est: -4.96 (-14.9%)
|
11.26
11.26 – 11.26
+327.0% YoY
|
11.26
11.26 – 11.26
+0.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 817.1K | 0.06% |
| 2 | Vanguard ESG International Stock ETF VSGX | 0.00% | 118.6K | 0.10% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 55.0K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 24.4K | 0.48% |
| 5 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 2.71M | 0.06% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 3.85M | 0.05% |
| 7 | Vanguard Total World Stock ETF VT | 0.00% | 193.4K | 0.06% |
| 8 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 4.4K | 0.22% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 13.1K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 7.1K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jagdish Parasrampuria | Senior Vice President of Pharmaceutics and Manufacturing | 5M | — |
| Wenjin Yang | Chief Scientific Officer and Director of New Drugs and R&D | 5M | — |
| Benjamin Chien | Founder, Chief Executive Officer & Chairman | 3M | — |
| Yisheng Lee | Chief Medical Officer & Director | 80.0K | — |
| Ruo Hua Huang | Deputy Manager of Investor Relations | — | male |
| Bassem Elmankabadi | Senior Vice President of Clinical Development | — | — |
| Yuhua Li | Co-founder & Chief Technology Officer | — | — |
| Mathieu Boudreau | Chief Operating Officer & Chief Business Officer | — | — |
| MengKung Chan | Chief Financial Officer | — | male |
| Ning Ya Chen | Accounting Supervisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6576.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
